Cell Therapeutics Options Show Record Bets on Drugmaker Retreat

Options traders are making record bets that Cell Therapeutics Inc. will extend a decade-long plunge that wiped out 99.96 percent of its value as the drugmaker undergoes a Feb. 10 review by U.S. regulators on its experimental cancer therapy.
BusinessWeek